American Battery Solutions, Inc.’s ESS Division Completes Spin-Out, Establishes American Energy Storage Innovations, Inc.
The new independent company charts enormous success with industry leader Bud Collins at the helm.
BOSTON and DETROIT, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Today, just ahead of the RE+ exhibition, American Battery Solutions, Inc. (ABS) is pleased to announce the spin-out of its Energy Storage Solutions Division (ABS-ESS) to create a new company: American Energy Storage Innovations, Inc. (AESI). This strategic move represents a significant milestone in the evolution of energy storage technology and underscores ABS’ commitment to driving innovation within the industry.
ABS was founded just four years ago by Subhash Dhar, a venerable 40-year battery industry veteran, and has consistently led the charge to advance cutting-edge energy storage technologies. Dhar, who remains actively engaged as a board member of the new venture, emphasized, "We nurtured and honed the unique potential embodied by TeraStor when we established the ESS Division, announced publicly just last year. Today, we fully recognize its potential, and are exhilarated to witness the autonomous ascent of AESI."
AESI (RE+ exhibitor booth 13100) will operate as a fully independent company, enjoying the continued support, confidence and backing of ABS' longstanding investors, the KCK Group. With an unwavering commitment to revolutionizing energy storage, AESI is poised to take center stage in the global energy transition and is set to redefine the future of energy storage technology.
The board of directors made the strategic decision to establish AESI as a distinct corporation, recognizing the incredible potential of the team’s groundbreaking technology and the immense growth opportunities on the horizon. By focusing exclusively on energy storage innovation, AESI will be better equipped to respond to the evolving demands of the market, accelerate technological advancements and drive the transition to sustainable energy solutions.
AESI will be helmed by Bud Collins, a highly respected industry leader with over 35 years of experience in developing and implementing power, energy and energy management solutions. Under his direction, AESI will draw upon the expertise of the same management team and technical experts who have played pivotal roles in ABS-ESS since its establishment in 2021. This core team of industry veterans has a longstanding working relationship with Collins, having collaborated at multiple companies, and together they have collectively overseen the successful execution of more than 1.5 gigawatt-hours of energy storage projects over the past 15+ years, worldwide.
What sets AESI apart is its inheritance of the extensive resources and capabilities developed within ABS-ESS, coupled with a dedicated institutional focus on pioneering energy storage technologies. AESI is committed to pushing the boundaries of innovation in energy storage and remains steadfast in its mission to drive sustainability and usher in a new era of energy solutions.
"We are thrilled to embark on this new journey as American Energy Storage Innovations," said Collins, CEO of AESI. "Our team's collective expertise and dedication to innovation will allow us to build on the strong foundation we created as ABS-ESS and make a significant impact on the energy storage industry. With the continued support of the KCK Group, we are poised to achieve remarkable success in shaping the future of energy storage technology."
This announcement marks a successful exit for ABS-ESS and represents a pivotal moment in the energy storage industry, signaling a commitment to innovation and sustainability. As AESI begins its journey as an independent company, it remains dedicated to pushing the boundaries of what is possible in energy storage, driving the global energy transition to new heights.
For more information on AESI and the 7.2 MWh (300MWh/acre) TeraStorTM, please visit booth 13100 at the RE+ exhibition or visit https://www.aesi-ess.com.
About American Energy Storage Innovations, Inc.
AESI is a pioneering provider of advanced energy storage solutions. The company designs, develops and manufactures cutting-edge systems, empowering customers to harness the full potential of renewable energy and optimize energy management. With a steadfast commitment to value, reliability, sustainability and innovation, the AESI team of industry veterans aims to revolutionize the energy storage landscape.
Contact
AESI Media Relations
American Energy Storage Innovations, Inc.
2 Cabot Road, Hudson, MA 01749 USA
media@aesi-ess.com
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote
Monument Reports Fourth Quarter and Fiscal 2023 Results29.9.2023 21:26:28 CEST | Press release
Gross Revenue of US$12.39 Million and Cash Cost of US$917/Oz for Gold Sulphide Production and US$1,622/Oz for Gold Oxide Production VANCOUVER, British Columbia, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) “Monument” or the “Company” today announced its annual financial results for the year ended June 30, 2023. All amounts are in United States dollars unless otherwise indicated (refer to www.sedar.com for full financial results). Cathy Zhai, the President and CEO commented, “Fiscal 2023 was a milestone year for the Company with the gold sulphide project completed, and the flotation plant was put into production at the Selinsing Gold Mine in Malaysia. The commercial production has also been reached in August 2023 subsequent to the year end. It again demonstrates Monument has been able to deliver what’s been promised and now we are ready for the next corporate move.” Fiscal Year 2023 Highlights: Construction of the Selinsing sulphide flotation pla
Nokia Corporation: Repurchase of own shares on 29.09.202329.9.2023 20:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 29 September 2023 at 21:00 EEST Nokia Corporation: Repurchase of own shares on 29.09.2023 Espoo, Finland – On 29 September 2023 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL319,5513.57CEUX58,3773.57AQEU11,0113.57TQEX4,7613.57Total393,7003.57 * Rounded to two decimals On 3 February 2022, Nokia announced that its Board of Directors is initiating a share buyback program under the authorization granted by Nokia’s Annual General Meeting on 8 April 2021 to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The second phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 5 April 2022 started on 2 Januar
EPH European Property Holdings PLC announces Unaudited Interim Results for the Six Months to 30 June 2023 and appointment of Management Committee Members29.9.2023 19:00:00 CEST | Press release
29 September 2023, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR BUSINESS HIGHLIGHTS FIRST HALF YEAR OF 2023 With an established portfolio of high-quality properties in prime locations in Europe occupied by tenants with strong credit ratings, combined with professional asset management, EPH European Property Holdings PLC (“EPH” or the “Company”) has demon-strated operational stability in the first six months of 2023, despite the ongoing market environment challenges. As a result, EPH not only achieved almost full occupancy throughout its European portfolio, it also increased rental income.The sale of the Company’s Russian portfolio was concluded in April 2023, following the Extraordinary General Meeting (held on 1 November 2022) at which the shareholders of EPH authorised the Board of Directors to sell EPH Group’s entire Russian property portfolio by way of a management buyout. Upon disposal of the Russian segment in the first half of 2023, the Company reclassified the
Oxurion Publishes First Half 2023 Results29.9.2023 19:00:00 CEST | Press release
Regulated Information Leuven, BELGIUM, Boston, MA, US –September 29, 2023 – 7.00PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today published its financial and business update for the six-month period ending June 30, 2023. The half-year report is available in the “Investors” section of the Company’s website and can also be downloaded as a PDF. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel